Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in active ankylosing spondylitis
NCT03502616Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib oral solution in ankylosing spondylitis (AS) (2 arms), sponsored by Pfizer. Primary endpoint: Assessment of SpondyloArthritis International Society 20 Response at 16 weeks. Started Jun 2018; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03502616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502616.